Passa al contenuto
Merck

L-ferritin: A theranostic agent of natural origin for MRI visualization and treatment of breast cancer.

Journal of controlled release : official journal of the Controlled Release Society (2020-01-04)
Valeria Bitonto, Diego Alberti, Roberto Ruiu, Silvio Aime, Simonetta Geninatti Crich, Juan Carlos Cutrin
ABSTRACT

The altered regulation of iron uptake and metabolism in cancerous cells, along with the potential of this metal to cause oxidative stress and cell death, makes iron overload an attractive therapeutic strategy for cancer treatment. In this study, the selective uptake of native HoS-ferritin (Horse-Spleen Ferritin) was assessed in TS/A breast cancer cells and compared with benign cystadenoma NMuMG. The higher expression of L-ferritin receptor SCARA5 led to an enhanced uptake in TS/A that is detected by the generation of a negative contrast in the corresponding MR images. The toxicity of HoS-ferritin toward TS/A cells has been investigated in detail in vitro, showing that cellular vitality is inversely related to the amount of internalized iron content. Finally, biodistribution and therapeutic efficacy of HoS-ferritin have been shown for the first time in vivo on a orthotopic breast cancer mice model, suggesting that iron overdose delivered by the HoS-ferritin can trigger selective mechanisms of regulated cell death.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
3,3′-Diiodo-L-thyronine (T2) hydrochloride, 98% (CP)